



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

SECTION COMMITTEE MEMBERS:

Chairperson: Prof. Dr. Pavel MOHR
Co-chairperson: Prof. Matej Stuhec
Secretary: Dr. Lucie BARTOVA

LIST OF SECTION MEMBERS:

Susan ABU DAYEH, Amman, Jordan
Ayodele ADEBAYO, Preston, United Kingdom
Dickson Olusegun ADEDEJI, Mosjøen, Norway
Joseph ADO-IMOISILI, ANTRIM, United Kingdom
Herta AGAJ, Lezhe, Albania
Harald AIFF, Gothenburg, Sweden
Süreyya AKYILDIRIM COR, Ankara, Türkiye
Badii AMAMOU, Monastir, Tunisia
Hugo AMARO, Basingstoke, United Kingdom
Mukesh AMBWANI, Karachi, Pakistan
A. Elif ANIL YAĞCIOĞLU, Ankara, Türkiye
Eric Kweku ARHINFUL, Winneba, Ghana
María Dolores ARIAS, Quito, Ecuador
Taha ARİK
Liana ARUSTAMYAN, Batumi, Georgia
Gozde AVCI BUYUKDOGAN, Istanbul, Türkiye
Mehtap AZ GENC, Izmir, Türkiye
Lucie BARTOVA, Vienna, Austria
Valentina BASILE, Orselina, Switzerland
Pierre BAUMANN, Prilly - Lausanne, Switzerland
Anzhela BAZZAEVA, г. Санкт-Петербург, Russian Federation
Hajer BEN MUSTAPHA, Etampes, France
Rolland BENJAMIN, BRON, France
Samrat Singh BHANDARI, Gangtok, India
Haije BIJ DE WEG, Leeuwarden, Netherlands
István BITTER, Budapest, Hungary
Amela BLEKIC, Portland, United States
Julio BOBES, Oviedo, Spain
Jacques A.j. BOERMANS
Erkan BOLAT, Ankara, Türkiye
Sovady BORA, Anthony, France
Claudio BRASSO, Turin, Italy
Matthew BROOME, Birmingham, United Kingdom
Martin BRUNOVSKY, Klecany, Czech Republic
Elena Daniela BUHAŞ RAMOCEA, Oradea, Romania
Aleksandra BURAS, Warsaw, Poland



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Ayça CAN UZ, İstanbul, Türkiye
Willys CANTENYS, PARIS, France
Marisa CASANOVA DIAS
Mirela ĆELIĆ RUŽIĆ, Zagreb, Croatia
Samet ÇETİN, ORDU, Türkiye
Sinem ÇETİN DEMİRTAŞ, Adana, Türkiye
Moussa Antoine CHALAH, Paris, France
Pritam CHANDAK, NAGPUR, India
Asterios CHASAPIS, Athens, Greece
Alessia CIANI, Brussels, Belgium
Masa COMIC
Boris CORIC, Kotor, Montenegro
Raul Alberto CORTES LADINO, Miami Beach, United States
Jürgen DE FRUYT, Brugge, Belgium
Marco DE TOFFOL, Matino (LE), Italy
Arie DE WERK, , Netherlands
Tugrul DEMIREGEN, Adana, Türkiye
Mustafa DİNÇER, AYDIN, Türkiye
Gizem DOGANCALI-YANCHEV, Pleven, Bulgaria
Luiz DRATCU, London, United Kingdom
Melike DÜZGÜN, Antalya, Türkiye
Jonas EBERHARD, Lund, Sweden
Emam EL-HIGAYA, Galway, Ireland
Defne ERASLAN, karlsruhe, Germany
Jacobus ERASMUS, West Melbourne, Australia
Damla ERBİL, Ankara, Türkiye
Allagoa EREFAGHA LEONARDO, Preston, United Kingdom
Muharrem ERGUN, chalon sur saone, France
Adedamola FASEHUN, Amherst, Canada
Luís Afonso FERNANDES, amadora, Portugal
Maria FILIP, Lodz, Poland
Igor FILIPCIC, Zagreb, Croatia
Przemysław FILIPIAK, Poznań, Poland
Michele FORNARO, New York, United States
Ehsan FOTOUHI ARDEKANI, Bad Zwischenahn, Germany
Beatrice FRAQUELLI, Monza, Italy
Silvana GALDERISI, Naples, Italy
Maria Paz GARCIA-PORTILLA GONZALEZ, Oviedo, Spain
Matteo GARI, Milano, Italy
Sundar GNANAVEL, Morpeth, United Kingdom
Marcos GÓMEZ-REVUELTA, Santander, Spain
Heinz GRUNZE, Weinsberg, Germany
Willem Cornelis Pieter GUIJT, Katwijk ZH
Ahmet GÜRCAN, Ankara, Türkiye



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Josep Maria HARO, Barcelona, Spain
Morten HATLEN, Bergen, Norway
Bruno HEMERLY, Governador Valadares, Brazil
Ayşegül Tuğba HıRA SELEN, KONYA, Türkiye
Jillian HOWLIN, Malmö, Sweden
Sofiya HRECHUKH, Lviv, Ukraine
Jan HUBENAK, Hradec Králové, Czech Republic
Laura IACOB
Bekzod IBADULLAYEV, Urgench, Uzbekistan
Zhuchenko IHOR, Vinnytsia, Ukraine
Claudia Romina IONESCU, Bucharest, Romania
Melina IORDACHE, Constanta, Romania
Angela IZQUIERDO DE LA PUENTE, Madrid, Spain
Marek JAREMA, n/a, Poland,
Eddynell JIMENEZ MANZUETA, MAO VALVERDE, Dominican Republic
Siegfried KASPER, Vienna, Austria
Ozge KILIC, Istanbul, Türkiye
Pınar KızıLAY ÇANKAYA, Ankara, Türkiye
Nikolaos KOKRAS, Athens, Greece
Halldor KOLBEINSSON, Reykjavik, Iceland
Volodymyr KOROSTIY, Kharkiv, Ukraine
Theodoros KOUTSOMITROS, Thessaloniki, Greece
Lukasz KOWALEWSKI, Dublin, Ireland
Ivan KOYCHEV, OXFORD, United Kingdom
Fabian KRAXNER, Hedingen, Switzerland
Anna Julia KRUPA, Krakow, Poland
Priyantha Namal LABUTALE, Bradford, United Kingdom
Desiree LACIDA, Davao City, Philippines
Aiste LENGVENYTE, Montpellier, France
Jona LEWIN, London, United Kingdom
Jan LIBIGER, Hradec Kralove, Czech Republic
Tino LINDNER, Utrecht, Netherlands
Antonella LITTA, Bari, Italy
Maxime LOGNOUL, Welkenraedt, Belgium
Livia Andreea LUPSA, Göteborg, Sweden
Marilena-petruta MAIDAN
Aram MAMIKONYAN, Yerevan, Armenia
Daniel MANDRI, Miami, Florida, United States
Daniel Felipe MARINO, Medellin, Columbia
Kamel MARZOUKI, LONDON, United Kingdom
Kotchuthressia MATHEW, Manjeri, India
Declan MCLOUGHLIN, Dublin, Ireland
Haque MD. RASHIDUL, Dhaka, Bangladesh
Antonio METASTASIO, London, United Kingdom



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Milos MILUTINOVIC, Skopje, North Macedonia
Dimitrie-filip MOGÎRZAN
Pavel MOHR, Klecany, Czech Republic
Hans-jürgen MÖLLER, München, Germany
Farshid MONSHIZADEH TEHRANI, Copenhagen, Denmark
Jonas MONTVIDAS, Kaunas, Lithuania
Marc NAIRZ-FEDERSPIEL, Wien, Austria
Dina NAOUM, cairo, Egypt
Shahid NAWAZ, Hamilton, United Kingdom
Boglarka ORBAN-SZIGETI
Laura ORSOLINI, Ancona, Italy
Galyna OSADCHA, Kyiv, Ukraine
Raul Felipe PALMA ALVAREZ, Barcelona, Spain
Igor PANTIĆ, Belgrade, Serbia
Kollarova PATRICIE
Irene PINUCCI, Rome, Italy
Chrysostomi Maria PLATSA, Greater London, United Kingdom
Lucian - Ioan POP, Romania
Milan POPOVIĆ, Beograd, Serbia
Goran RACETOVIĆ, Prijedor, Bosnia and Herzegovina
Zoheb RAJ, Sharjah, United Arab Emirates
Adeosun RITA, Linz, Austria
Tyson RIZZARDO, New Westminster, Canada
Sara RODRIGUES, Porto, Portugal
Janusz K. RYBAKOWSKI, Poznan, Poland
Farzaneh SAEEDZADEH SARDAHAEE, Trondheim, Norway
Şengül ŞAHİN, Gaziantep, Türkiye
Hamza SALEMI, kabul, Afghanistan
Virginio SALVI, Crema, Italy
Andriy V. SAMOKHVALOV, Guelph, Canada
Peter SANTOS, Cagayan de Oro, Philippines
Samuel SARRAZIN, ALFORTVILLE, France
Aleksandar SAVIC, Zagreb, Croatia
Gianluca SERAFINI, Genoa, Italy
Angelo Vincenzo SERIO, Massafra, Italy
Karthik SHESHACHALA, Melbourne, Australia
Habibullah Aimal SHINWARI, Kabul, Afghanistan
Sarfaraz Aslam SHORA, Bradford, United Kingdom
Francis SILVEIRA, Governador Valadares MG, Brazil
Sumeet SINGH, Pathankot, India
Marcin SIWEK, Kraków, Poland
Anthony SOARES, London, United Kingdom
Amro SOLIMAN, Cairo, Egypt
Iryna SOVYCH



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Aldo STOPPA, BARCELONA, Spain
Matej Stuhec, Ormoz, Slovenia
Züleyha SUSAM, Düsseldorf, Germany
Attila SZABO, Oslo, Norway
Petra Andrea SZILAGYI, Budapest, Hungary
Hina TAHSEEN, Knutsford, United Kingdom
Cristiana TAPOI, Bucharest, Romania
Florence THIBAUT, PARIS, France
Sovannridh THIM, Versailles, France
Shruti TIWARI, New York, United States
Agata TODZIA-KORNAŚ, Warszawa, Poland
Ngoc TRAN
Tamas TREUER, Budapest, Hungary
Doina VACALIE, Frederikssund, Denmark
Simavi VAHIP, Izmir, Türkiye
Octavian VASILIU, Bucharest, Romania
María Isabel VÁSQUEZ-SUYO, Lima, Peru
Timothy VEAL, La Jolla, United States
Ramachandra VENKATESHWARA, Plymouth, United Kingdom
Petar VIDOVIĆ
Andreja VUCHKOV, Toorak, Australia
Rebecca WARD
Angelika WIECK, Manchester, United Kingdom
Damla YILDIRIM
İmran Gökçen YILMAZ KARAMAN, Eskişehir, Türkiye
Virginia YOUSSEF
Nikola ŽAJA, Zagreb
Besmira ZENELAJ, Tirana, Albania

LAST SECTION COMMITTEE ELECTIONS HELD:

Date: 08 April 2024
Venue: EPA Congress Budapest, Hungary

ACTIVITIES OF THE SECTION IN 2025:

Meetings/events

Section Business Meeting

Description:

The section held one in-person meeting during the annual EPA Congress in Madrid, Spain, on 6th April 2025.

Location: 33rd EPA Congress, Madrid (Spain)



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Start date: 06/04/2025

End date: 06/04/2025 **Attendance:** 9

Section Symposium: Are side effects needed for efficacy in psychiatric treatments?

Description: This session was organized by the Section on Psychopharmacology.

Chairs: Pavel Mohr (Czech Republic), Lucie Bartova (Austria)

Speakers: István Bitter (Hungary), Siegfried Kasper (Austria), Veronika Andrashko (Czech Republic), Jose Antoni Ramos-Quiroga (Spain)

Description: Since the introduction of the first psychotropic drugs into clinical practice, psychiatrists have struggled to find the optimum balance between wanted and unwanted effects. This symposium critically examined the relationship between therapeutic and adverse effects of psychotropics in treating various mental disorders, including depression, schizophrenia, and substance use disorders.

Location: 33rd EPA Congress, Madrid (Spain)

Start date: 06/04/2025

End date: 06/04/2025

Joint Symposium: Therapeutic drug monitoring issues in clinical practice: from adulthood to elderly age

Description:

This session was jointly organized by the Section on Old Age Psychiatry and the Section on Psychopharmacology

Chairs: Lucie Bartova (Austria), Matej Štuhec (Slovenia)

Speakers: Georgios Schoretsanitis (Switzerland), Matej Štuhec (Slovenia), Pavel Mohr (Czech Republic), Jens Benninghoff (Germany), István Bitter (Hungary)

Description: Therapeutic drug monitoring (TDM) involves measuring drug concentrations in plasma and is a valuable method for individualizing doses in patients. This workshop focused on the practical aspects of TDM use in clinical practice, particularly dose adjustments and recognizing drug-drug interactions. The structure included a case presentation and audience interaction via tools like Mentimeter.

Location: 33rd EPA Congress, Madrid (Spain)

Start date: 06/04/2025

End date: 06/04/2025



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Section Symposium: Psychopharmacology for depression and anxiety in the medically ill patient

Description:

This session was jointly organized by the Section on Consultation Liaison Psychiatry and Psychosomatics and the Section on Psychopharmacology.

Chairs: Pavel Mohr (Czech Republic), Diogo Telles Correia (Portugal)

Speakers: Lucie Bartova (Austria), Filipa Novais (Portugal), Matej Štuhec (Slovenia), Giorgio Mattei (Italy)

Description: The symposium addressed the management of anxiety and depressive symptoms in patients with primary somatic diseases, focusing on pharmacodynamics and pharmacokinetic issues of antidepressants, interactions with non-psychotropic medications, and integration with psychotherapeutic strategies. Presentations included clinical vignettes and case-based treatment recommendations.

Location: 33rd EPA Congress, Madrid (Spain)

Start date: 08/04/2025

End date: 08/04/2025

Section Webinar: Evidence-Based Diagnosis and Treatment of Treatment-Resistant Depression – Update and Preview

Description:

This webinar was organized by the Section on Psychopharmacology.

Chairs: Lucie Bartova (Austria), Siegfried Kasper (Austria)

Speakers: Georg Kranz (Hong Kong), Pia Baldinger-Melich (Austria), Christoph Kraus (Austria)

Target Audience: Clinical Psychiatrists and Neuroscientists at all career stages.

Description: Major depressive disorder (MDD) is a common psychiatric condition with a significant subset of patients experiencing treatment-resistant depression (TRD). The webinar addressed diagnostic challenges, including the exclusion of pseudoresistance, and provided an overview of evidence-based pharmacological and non-pharmacological treatments, including innovative approaches.

Location: Online

Start date: 27/10/2025

End date: 27/10/2025



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Development of Educational Resources

Description:

Participation in the creation of the European Training Requirements for Psychopharmacology and an updated curriculum program for 2025, contributing to the development of the European Board Examination in Psychiatry.

Location: diverse

Start date: 01/01/2025

End date: 31/12/2025

Joint Symposium EPA – Spanish NPA: Towards Real-World Solutions in Mental Health Description:

Mohr P. Hot topics in psychopharmacology: European perspective.

Location: 33rd EPA Congress, Madrid (Spain)

Start date: 05/04/2025 **End**

date: 08/04/2025

Prescribing and deprescribing antipsychotics for psychotic disorders: Focus on schizophrenia

Description:

This session was organized by the Section on Psychopharmacology.

Chairs: István Bitter (Hungary), Matej Štuhec (Slovenia)

Description: The interactive format of the course focused on the following subtopics, which were discussed with the participants:

Part I. Pharmacology

- Clinically relevant information on neurotransmitters
- Different formulations of AP
- How to define the appropriate dose of an AP for a patient?
- Benefits of therapeutic (plasma level) drug monitoring

Part II. Efficacy and effectiveness of AP

- How do patients, family members, and health care team members define efficacy?
- Pharmacological treatment of positive and negative symptoms including agitation and suicidal behavior of schizophrenia
- Acute and maintenance treatment in schizophrenia



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

- Response, remission and treatment resistance

Part III. Safety and tolerability of AP

- Preventions and management of the most common side effects and drug-drug interactions during AP treatment

Part IV. Prescribing and deprescribing AP and other medications

- AP treatment: monotherapy; combining or switching antipsychotics for nonresponse. Clozapine treatment.

- What is the duration of AP treatment in schizophrenia?

- How to discontinue/deprescribe AP treatment?

Location: 33rd EPA Congress, Madrid (Spain)

Start date: 05/04/2025

End date: 08/04/2025

Publications

The Role of Pharmacotherapy in the Management of Comorbidities.

Journal:

In: Fiorillo, A.; Javed, A.; Sartorius, N. (Ed.): Comorbidity between Mental and Physical Disorders: Identification, Management and Treatment. 1st ed. Basel, Cham: Springer, 2025, s. 411-430. ISBN 978-3-031-81801-1. DOI: 10.1007/978-3-031-81802-8_18.

Authors:

BITTER, Istvan; MOHR, Pavel; STUHEC, Matej

(Expected) Publication date: 01/01/2025

Acknowledged as official Section publication? Yes

Other Section activities

Description:

EPA Online Talks with Experts Meeting

Event Start date: 01/01/2025

Event End date: 01/01/2025 **Outcomes**

Continued collaboration with the EPA Early Career Psychiatrists Section for online expert talks.



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Description:

Participation at the 11th EAN Congress 2025 in Helsinki, Finland, in the joint EAN/EPA Symposium: Brain and mental health across the lifespan: A neuropsychiatric perspective

Presentation: Mohr P. Bridging neurology and psychiatry: The case for integrated brain health. 11th Congress of the European Academy of Neurology (EAN), Helsinki, Finland, June 21-24, 2025.

Event Start date: 21/06/2025

Event End date: 24/06/2025

Description:

Collaboration with EMA

Event Start date: 01/01/2025

Event End date: 01/01/2025

Outcomes

Contribution by Pavel Mohr to the EPA's statement supporting recommendation for the approval of lecanemab.

FUTURE ACTIVITIES:

Meetings/events

Section Business Meeting

Description:

The section will hold one in-person meeting during the annual EPA Congress in Prague, Czechia, on 29th March 2026.

Location: 34th EPA Congress, Prague (Czechia)

Start date: 28/03/2026

End date: 31/03/2026



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Course: Pharmacotherapy of depression (and beyond): the art of prescribing antidepressants

Description:

This course has already been accepted.

This is session organized by the Section on Psychopharmacology.

Date: 28.03.2026 | 13:30 - 17:00 | South Room 223+4

Code: C006

Topic: Educational

Chairs: Pavel Mohr (Czech Republic), Lucie Bartova (Austria)

Description: This interactive, evidence-based course is a “follow-up” of the previous popular course on antipsychotic treatment, organised by the Psychopharmacology Section at several past EPA Congresses. The primary target audience is early career psychiatrists, but it may be also of interest to more experienced prescribers who want to deepen their knowledge and become familiar with the latest developments in the field. The course is divided into several topics that cover novel nomenclature of antidepressants, (NbN), their pharmacology, clinical efficacy and safety, potential drug-drug interactions, treatment in specific situations (children and adolescents, elderly), evaluation of treatment response, management of non-response. In addition to the antidepressant drugs, other treatment interventions (herbal remedy, neurostimulation, psychedelics) will be briefly discussed.

Location: 34th EPA Congress, Prague (Czechia)

Start date: 28/03/2026

End date: 28/03/2026

Joint Symposium: Coming of age: pharmacotherapy during transition from adolescence to adulthood

Description:

This session has already been accepted.

- This is a joint symposium organized by the Section on Psychopharmacology and the Section on Child- and Adolescent Psychiatry.

Date: 29.03.2026 | 08:00 - 09:30 | South Hall 1A + South Hall 1B

Code: SP02

Topic: Clinical/Therapeutic

Chairs: Judit Balazs (Hungary), Pavel Mohr (Czech Republic) Speakers: Celso Arango (Spain), Judit



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Balazs (Hungary), Pavel Mohr (Czech Republic), Hana Papezova (Czech Republic)

Speakers: Celso Arango (Spain), Judit Balazs (Hungary), Pavel Mohr (Czech Republic), Hana

Papezova (Czech Republic) Presentation titles:

Present and future treatments in ASD. What we have and what we need (Speaker: Celso Arango, Spain)

Antidepressant treatment during transition from adolescence to adulthood (Speaker: Judit Balazs, Hungary)

Antipsychotics during transition from adolescence to adulthood (Speaker: Pavel Mohr, Czech Republic)

Pharmacotherapy of Eating Disorders during transition from adolescence to adulthood (Speaker: Hana Papezova, Czech Republic)

Location: 34th EPA Congress, Prague (Czechia)

Start date: 29/03/2026

End date: 29/03/2026

Core Symposium: Pharmacological aspects in diverse groups

Description:

This core symposium has already been accepted.

Date: 29.03.2026 | 17:00 - 18:30 | South Hall 3

Code: CRS03

Topic: Educational

Chairs: Jerzy Samochowiec (Poland), Simavi Vahip (Turkey)

Speakers: Dinesh Bhugra (United Kingdom), Eva Döring-Brandl (Germany), Pavel Mohr (Czech Republic), Meryam Schouler-Ocak (Germany)

Location: 34th EPA Congress, Prague (Czechia)

Start date: 29/03/2026

End date: 29/03/2026

How to start the rest of your career as a psychiatrist: A few words with those who made it

Description:



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

This workshop has already been accepted.

This is a workshop organized by the Section on Early Career Psychiatrists.

Date: 30.03.2026 | 17:00 - 18:30 | Terrace 2A

Code: ECP07

Topic: Educational

Chairs: Federico Mucci (Italy), Giulio Longo (Italy)

Speakers: Sinan Guloksuz (Netherlands), Cécile Hanon (France), Fabian Kraxner (Switzerland), Pavel Mohr (Czech Republic)

Location: 34th EPA Congress, Prague (Czechia)

Start date: 30/03/2026

End date: 30/03/2026

Case-based Workshop: Clinical insights into drug-drug interactions: prescribing recommendations for daily practice Description:

This workshop has already been accepted.

This is a joint workshop organized by the Section on Psychopharmacology and the Section on Old Age Psychiatry.

Date: 31.03.2026 | 10:00 - 11:30 | Forum Hall

Code: CBS04

Topic: Pharmacology

Chairs: Matej Stuhec (Slovenia), Gabriela Stoppe (Switzerland)

Speakers: Georgios Schoretsanitis (Switzerland), Matej Stuhec (Slovenia), Pavel Mohr (Czech Republic), Gabriela Stoppe, (Switzerland), Istvan Bitter (Hungary), Cécile Hanon (France)

Presentation titles:

Clinical case and drug-drug interactions in the elderly: a case report (Speaker: Georgios Schoretsanitis, Switzerland)

Pharmacokinetic and Pharmacodynamic Interactions: From Theory to Practice (Speaker: Matej Stuhec, Slovenia)



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Assessing Drug-Drug Interactions in Adjunctive Antidepressant Treatment: Clinical Perspectives (Speaker: Pavel Mohr, Czech Republic)

Pharmacological Challenges and Clinical Strategies in Adjunctive Dementia Therapy based on Drug-Drug Interactions (Speaker: Gabriela Stoppe, Switzerland)

Evaluating Drug-Drug Interactions in Adjunctive Antipsychotic Therapy (Speaker: Istvan Bitter, Hungary)

Drug-drug interactions in nursing homes (Speaker: Cécile Hanon, France)

Location: 34th EPA Congress, Prague (Czechia)

Start date: 31/03/2026

End date: 31/03/2026

Psychiatrist treatment choices vs. Guidelines in the treatment of schizophrenia in different phases and clinical situations

Description:

This workshop has already been accepted.

Date: 31.03.2026 | 08:00 - 09:30 | Forum Hall

Code: WS09

Topic: Clinical/Therapeutic

Chairs: Martina Rojnic Kuzman (Croatia), Peter Falkai (Germany)

Speakers: Pavel Mohr (Czech Republic), Silvana Galderisi (Italy), Angelika Wieck, United Kingdom), Martina Rojnic Kuzman (Croatia), Peter Falkai (Germany), Merete Nordentoft (Denmark) Presentation titles:

Evidence-based treatment for treatment resistant schizophrenia (Speaker: Pavel Mohr, Czech Republic)

Evidence-based treatment of negative and cognitive symptoms in schizophrenia (Speaker: Silvana Galderisi, Italy)

How to manage pregnancy in schizophrenia (Speaker: Angelika Wieck, United Kingdom)

Psychiatrist schizophrenia treatment choices vs. guidelines: Results from the Ambassador study (Speaker: Martina Rojnic Kuzman, Croatia)

Evidence-based treatment for metabolic side-effects of antipsychotics (Speaker: Peter Falkai, Germany)

Evidence-based treatment in prodromal phase of schizophrenia (Speaker: Merete Nordentoft, Denmark)



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2025

Location: 34th EPA Congress, Prague (Czechia)

Start date: 31/03/2026

End date: 31/03/2026

FUNDING IN 2025

Income: None

Source(s) of funding:

None

Expenditure: None

Balance: None

EPA Treasurer audit: No

Confirmation that income / expenditure is via EPA: No